Follicular Lymphoma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 302

Follicular Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Follicular Lymphoma - Pipeline Review, H2 2012', provides an overview of the Follicular Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Follicular Lymphoma. 'Follicular Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Follicular Lymphoma.
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Follicular Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Follicular Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Follicular Lymphoma Therapeutic Products under Development, Key Players in Follicular Lymphoma Therapeutics, Follicular Lymphoma Pipeline Overview, Follicular Lymphoma Pipeline, Follicular Lymphoma Pipeline Assessment

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Follicular Lymphoma Overview 10
An Overview of Pipeline Products for Follicular Lymphoma 11
Follicular Lymphoma Therapeutics under Development by Companies 13
Follicular Lymphoma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Follicular Lymphoma Therapeutics – Products under Development by Companies 24
Follicular Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in Follicular Lymphoma Therapeutics Development 32
Bristol-Myers Squibb Company 32
F. Hoffmann-La Roche Ltd. 33
Abbott Laboratories 34
Sanofi-Aventis 35
Eli Lilly and Company 36
GlaxoSmithKline plc 37
Antigenics, Inc. 38
Merck & Co., Inc. 39
Emergent BioSolutions Inc. 40
Lentigen Corporation 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
Pfizer Inc. 44
Cell Therapeutics, Inc. 45
Genmab A/S 46
Celgene Corporation 47
Bayer AG 48
IMMUNOMEDICS, INC 49
Accentia Biopharmaceuticals, Inc. 50
Pharmacyclics, Inc. 51
Memgen, LLC. 52
Ascenta Therapeutics, Inc. 53
CureTech Ltd. 54
Cylene Pharmaceuticals, Inc. 55
Follicular Lymphoma – Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 63
Enzastaurin - Drug Profile 63
MAbThera - Drug Profile 65
ABT-263 - Drug Profile 67
Prophage - Drug Profile 69
PCI-24781 - Drug Profile 71
SAR245409 - Drug Profile 73
BiovaxID - Drug Profile 75
ISF35 Vaccine - Drug Profile 77
BMS-936564 - Drug Profile 78
CT-011 - Drug Profile 79
Autologous FL Vaccine - Drug Profile 80
Rituximab + Radiation Therapy - Drug Profile 81
VR-CHOP - Drug Profile 82
Clofarabine - Drug Profile 84
1018 ISS + Rituxan - Drug Profile 85
Cyclophosphamide + Filgrastim - Drug Profile 87
Rituximab - Drug Profile 88
Velcade + Rituximab - Drug Profile 89
Velcade + Rituximab + Zevalin - Drug Profile 90
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 92
Rituximab + Denileukin Diftitox - Drug Profile 94
LBH589 + RAD001 - Drug Profile 95
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 97
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 99
Therapeutic Allogeneic Lymphocytes - Drug Profile 100
LG740 - Drug Profile 101
Rituximab + 90Y-Zevalin Radioimmunotherapy - Drug Profile 102
Velcade + Rituximab - Drug Profile 103
Inotuzumab Ozogamicin + Rituxan - Drug Profile 105
RG7159 + Bendamustine - Drug Profile 107
Velcade + Bendamustine + Rituximab - Drug Profile 109
Pixantrone + Rituximab - Drug Profile 111
RG7159 + Fludarabine + Cyclophosphamide - Drug Profile 112
Fludarabine + Mitoxantrone + Rituximab + Zevalin + Dexamethasone - Drug Profile 114
Bendamustine + Mitoxantrone + Rituximab - Drug Profile 116
AT-101 + Rituxan - Drug Profile 117
Rituximab + Dexamethasone - Drug Profile 118
Rituximab + Ifosfamide + Carboplatin + Etoposide + G-CSF + Plerixafor - Drug Profile 122
Rituximab + Galiximab - Drug Profile 124
Rituximab + Revlimid - Drug Profile 125
Revlimid - Drug Profile 127
Epratuzumab + Rituximab - Drug Profile 129
Rituximab - Drug Profile 130
Zevalin + Rituximab - Drug Profile 132
Bevacizumab + Rituximab - Drug Profile 133
Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 134
VELCADE-R-CAP - Drug Profile 136
Arzerra - Drug Profile 138
Cyclophosphamide + Vincristine + Prednisolone + Mabthera + Radiotherapy - Drug Profile 142
Rituxan - Drug Profile 144
RAD001 + Revlimid - Drug Profile 145
QS21 + Autologous Tumor Cell Vaccine - Drug Profile 146
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 148
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile 150
R-CHOP + Tositumomab + Iodine I 131 Tositumomab - Drug Profile 152
Galiximab + Rituximab - Drug Profile 154
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 161
VELCADE-R-CP - Drug Profile 163
Arzerra + CHOP - Drug Profile 165
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 167
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 169
Nelfinavir + Bortezomib - Drug Profile 173
Zevalin + Rituximab - Drug Profile 174
Rituximab + Bendamustine - Drug Profile 175
Epratuzumab + Rituximab - Drug Profile 176
Veltuzumab + Yttrium-90-Labelled-Epratuzumab - Drug Profile 178
AME-133v - Drug Profile 180
Fludarabine + Velcade + Rituximab - Drug Profile 181
R-BMD - Drug Profile 182
Lenalidomide + R-CHOP - Drug Profile 184
Temsirolimus + Rituximab + Bendamustine - Drug Profile 188
Bortezomib + BCVP-R Regimen - Drug Profile 190
Rituximab + Sargramostim - Drug Profile 192
Ofatumumab - Drug Profile 194
R-FM - Drug Profile 201
Id-KLH Vaccine + QS-21 - Drug Profile 202
R-CVP - Drug Profile 203
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Zevalin - Drug Profile 212
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine + Rituxan + GM-CSF - Drug Profile 214
R-CHOP - Drug Profile 215
Velcade + Rituximab - Drug Profile 217
Rituximab + Bendamustine Hydrochloride - Drug Profile 218
Rituximab + Bendamustine Hydrochloride + Bortezomib - Drug Profile 219
Rituximab + Bendamustine Hydrochloride + Lenalidomide - Drug Profile 221
Ofatumumab - Drug Profile 223
CX-5461 - Drug Profile 224
Revlimid + Rituxan - Drug Profile 225
Rituximab + Radiation Therapy - Drug Profile 226
Ofatumumab - Drug Profile 227
Bendamustine + Rituximab + 90-Yttrium Ibritumomab Tiuxetan - Drug Profile 228
GP2013 - Drug Profile 230
HCD122 + Bendamustine - Drug Profile 231
Ofatumumab + Bendamustine Hydrochloride - Drug Profile 232
Ofatumumab + Bendamustine Hydrochloride + Bortezomib - Drug Profile 233
Rituximab + Lenalidomide - Drug Profile 235
Amplimexon - Drug Profile 236
Rituximab + Bendamustine - Drug Profile 237
TRU-016 + Rituximab + Bendamustine - Drug Profile 238
Temsirolimus + Rituximab + Bortezomib + Dexamethasone - Drug Profile 242
Methotrexate + Bexxar - Drug Profile 244
LBH589 - Drug Profile 245
Autologous Effector Lymphocytes + Rituximab - Drug Profile 246
Rituximab + Cyclophosphamide + Fludarabine + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 248
MK-8808 + Cyclophosphamide + Vincristine + Prednisolone - Drug Profile 250
MK-8808 - Drug Profile 252
Rituximab + Bendamustine - Drug Profile 253
Vidaza + Revlimid - Drug Profile 254
Ofatumumab + Bortezomib - Drug Profile 256
R-CHOEP14x6+HD-AraC+HD-Mtx - Drug Profile 257
Rituximab - Drug Profile 259
Follicular Lymphoma Therapeutics – Drug Profile Updates 260
Follicular Lymphoma Therapeutics – Discontinued Products 278
Follicular Lymphoma Therapeutics - Dormant Products 279
Follicular Lymphoma – Product Development Milestones 283
Featured News & Press Releases 283
Appendix 293
Methodology 293
Coverage 293
Secondary Research 293
Primary Research 293
Expert Panel Validation 293
Contact Us 294
Disclaimer 294

List of Tables
Number of Products Under Development for Follicular Lymphoma, H2 2012 19
Products under Development for Follicular Lymphoma – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 28
Comparative Analysis by Late Stage Development, H2 2012 29
Comparative Analysis by Mid Clinical Stage Development, H2 2012 30
Comparative Analysis by Early Clinical Stage Development, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Development by Companies, H2 2012 (Contd..1) 33
Products under Investigation by Universities/Institutes, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 39
Bristol-Myers Squibb Company, H2 2012 40
F. Hoffmann-La Roche Ltd., H2 2012 41
Abbott Laboratories, H2 2012 42
Sanofi-Aventis, H2 2012 43
Eli Lilly and Company, H2 2012 44
GlaxoSmithKline plc, H2 2012 45
Antigenics, Inc., H2 2012 46
Merck & Co., Inc., H2 2012 47
Emergent BioSolutions Inc., H2 2012 48
Lentigen Corporation, H2 2012 49
Millennium Pharmaceuticals, Inc., H2 2012 50
Novartis AG, H2 2012 51
Pfizer Inc., H2 2012 52
Cell Therapeutics, Inc., H2 2012 53
Genmab A/S, H2 2012 54
Celgene Corporation, H2 2012 55
Bayer AG, H2 2012 56
IMMUNOMEDICS, INC, H2 2012 57
Accentia Biopharmaceuticals, Inc., H2 2012 58
Pharmacyclics, Inc., H2 2012 59
Memgen, LLC., H2 2012 60
Ascenta Therapeutics, Inc., H2 2012 61
CureTech Ltd., H2 2012 62
Cylene Pharmaceuticals, Inc., H2 2012 63
Assessment by Monotherapy Products, H2 2012 64
Assessment by Combination Products, H2 2012 65
Assessment by Stage and Route of Administration, H2 2012 67
Assessment by Stage and Molecule Type, H2 2012 70
Follicular Lymphoma Therapeutics – Drug Profile Updates 268
Follicular Lymphoma Therapeutics – Discontinued Products 286
Follicular Lymphoma Therapeutics – Dormant Products 287
Follicular Lymphoma Therapeutics – Dormant Products (Contd..1) 288
Follicular Lymphoma Therapeutics – Dormant Products (Contd..2) 289
Follicular Lymphoma Therapeutics – Dormant Products (Contd..3) 290

List of Figures
Number of Products under Development for Follicular Lymphoma, H2 2012 19
Products under Development for Follicular Lymphoma – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 24
Late Stage Products, H2 2012 29
Mid Clinical Stage Products, H2 2012 30
Early Clinical Stage Products, H2 2012 31
Assessment by Monotherapy Products, H2 2012 64
Assessment by Combination Products, H2 2012 65
Assessment by Route of Administration, H2 2012 66
Assessment by Stage and Route of Administration, H2 2012 67
Assessment by Molecule Type, H2 2012 68
Assessment by Stage and Molecule Type, H2 2012 69

Customers who bought this item also bought

• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012
• Cytopenia - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Myeloproliferative Disorders - Pipeline Review, H2 2012
• Systemic Lupus Erythematosus - Pipeline Review, H2 2012